Upadacitinib 30mg modified-release tablets
NHS hospitals in England used £102,206,026 of indicative cost of Upadacitinib 30mg modified-release tablets in the 12 months to April 2026, about 0.4% of all hospital medicines spend. That is up 60.7% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Upadacitinib 30mg modified-release tablets: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Upadacitinib 30mg modified-release tablets most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Guy's & St Thomas' Nhs Foundation Trust | £3,019,333 |
| Salford Royal Nhs Foundation Trust | £2,880,373 |
| Barts Health Nhs Trust | £2,878,361 |
| Oxford University Hospitals Nhs Ft | £2,558,661 |
| Univ Hpls Bristol Nhs Foundation Trust | £2,433,662 |
| King's College Hpl Nhs Foundation Trust | £2,424,962 |
| Univ Hpl B/Ham Nhs Foundation Trust | £2,285,963 |
| Gloucestershire Hpls Nhs Foundation Trst | £2,082,518 |
| Leeds Teaching Hpls Nhs Trust | £2,049,198 |
| Hull And East Yorkshire Hpls Nhs Trust | £1,880,032 |
The primary-care picture
Upadacitinib is also dispensed in the community. See the national primary-care prescribing volume, cost and trend on the Upadacitinib medicine page.